Breast Cancer Clinical Trial
Official title:
Computerized Cognitive Training in Breast Cancer Survivors
NCT number | NCT05570604 |
Other study ID # | IUSCC-0625 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | May 17, 2017 |
Est. completion date | March 20, 2020 |
Verified date | October 2022 |
Source | Ohio State University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
For millions of cancer survivors, cognitive impairment is a prevalent, severe, and persistent problem that is associated with other symptoms (depressive symptoms, anxiety and fatigue), poorer work ability, and poorer quality of life. Available evidence, including work by the investigators own group, suggests that cognitive training may be a viable treatment option. However, to date, these studies are limited as none have been conducted in the home and therefore fail to address the transferability of these empirically based cognitive training programs to general practice. The purpose of this translational research is to conduct a home based single-blind, randomized controlled trial to test the feasibility, satisfaction, and preliminary efficacy of cognitive training compared to attention control in breast cancer survivors (BCS) as well as to explore potential biomarkers of intervention effects. This research innovatively builds on investigator's previous research by: 1) translating findings from the laboratory to the home setting and importantly seeks to identify facilitators and barriers of intervention use; 2) addresses limitations of previous trials (uses an attention control rather than a no-contact or wait-list control), (3) examines cognitive training effects on real-life outcomes such as associated symptoms, perceived work ability and quality of life; and (4) will be the first study in cancer survivors to explore levels of BDNF as a potentially sensitive outcome measure of intervention effects over time compared to attention control. Findings from this study will provide necessary information about the feasibility, satisfaction and preliminary efficacy of the home-based cognitive training on memory performance and processing speed as well as its effects on associated outcomes in BCS. Positive results will lead to a larger, full-scale study to determine efficacy and build evidence-based treatment for clinicians to use in treating BCS with cognitive impairment.
Status | Completed |
Enrollment | 68 |
Est. completion date | March 20, 2020 |
Est. primary completion date | March 20, 2020 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 21 Years and older |
Eligibility | Inclusion Criteria: 1. Female gender 2. = 21 years old at the time of informed consent 3. Ability to provide written informed consent and HIPAA authorization 4. First diagnosis of non-metastatic breast cancer. 5. Self-reported cognitive impairment 6. Subjects seeking treatment though not currently being treated or with prior treatment history for cognitive impairment. 7. = 1 year post-treatment including surgery, radiation, and/or chemotherapy 8. Ability to understand, speak, read, and write English Exclusion Criteria: 1. Comorbidities that would sufficiently impair performance or inhibit cognitive training such as: history of stroke, encephalitis, traumatic brain injury, brain surgery, dementia, or Alzheimers disease. 2. Cranial radiation or intrathecal therapy. 3. Current active major depression or substance abuse or history of bipolar disorder psychosis, schizophrenia, or learning disability. 4. History of current or other cancer except for basal cell skin cancer. |
Country | Name | City | State |
---|---|---|---|
United States | Indiana University School of Nursing | Indianapolis | Indiana |
Lead Sponsor | Collaborator |
---|---|
Ohio State University | Indiana University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Rey Auditory Verbal Learning Test (Rey AVLT) Total | Measure of learning and episodic memory. List of 15 words given and asked to recall, score range from 0-15. Higher scores indicate better outcomes. | Baseline and within 1 week post-intervention | |
Other | Rey Auditory Verbal Learning Test (Rey AVLT) Delayed | Measure of delayed memory. List of 15 words given and asked to recall at delayed timeframe, score range from 0-15. Higher scores indicate better outcomes. | Baseline and within 1 week post-intervention | |
Other | Rivermead Behavioral Paragraph Recall Test | Measure of immediate memory. 14-item test with score range from 0-12. Higher scores indicate better outcomes. | Baseline and within 1 week post-intervention | |
Other | Rivermead Behavioral Paragraph Recall Test -Delayed | Measure of delayed memory. 14-item test with score range from 0-12. Higher scores indicate better outcomes. | Baseline and within 1 week post-intervention | |
Other | Symbol Digit Modalities Test [SDMT], Oral Response Version | Measure of speed of processing. 90 seconds to pair numbers and figures, score range 0-110. Higher scores indicate better outcomes. | Baseline and within 1 week post-intervention | |
Other | Digit Span, total raw score from the WAIS-III | Measure of attention and working memory. Repetition of number sequence, score range from 0-15. Higher scores indicate better outcomes. | Baseline and within 1 week post-intervention | |
Other | Controlled Oral Word Association (COWA) | Measure of verbal/executive functioning. Provide a spontaneous list of words within 60 seconds, score range from 0-60. Higher scores indicate better outcomes. | Baseline and within 1 week post-intervention | |
Other | Serum levels of Brain-Derived Neurotropic Factor (BDNF) | Plasma levels of BDNF were measured in duplicate by ELISA (catalog number DBD00; R&D Systems, Minneapolis, MN). The minimum detectable level of BDNF in this assay is 20 pg/ ml, and the within-assay variation is 4.2% at 1339 pg/ml. Higher levels indicate higher concentrations of BDNF (reported in pg/ml). | Baseline and within 1 week post-intervention | |
Primary | Client Satisfaction Questionnaire | Likert-based 8-item questionnaire rating overall satisfaction, quality of training, etc. 4-point scale (range from 8-32) with higher scores indicating greater acceptability and satisfaction. | Within 1 week post-intervention | |
Secondary | Patient Reported Outcomes Measurement Information System (PROMIS) Cognitive Abilities and Cognitive Concerns | Perceived Cognitive Impairment (PCI) measured using 8-item, 5-point Likert scales with range from 8-40. The Cognitive Abilities Scale items target positive self-assessments of cognitive functioning with higher scores indicating better cognitive ability. The Cognitive Concerns Scale items are worded negatively and express concerns in the same area with higher scores indicating more cognitive concerns. | Baseline and within 1 week post-intervention | |
Secondary | Work Ability Index (WAI) | Work ability was assessed by one item from the WAI. This item assessed current work ability on a Likert scale from 1 (cannot work at all) to 10 (work ability at its best) with higher scores indicating better work ability. | Baseline and within 1 week post-intervention | |
Secondary | Medical Outcomes Study-Short-Form Health Survey (MOS SF-36) | General Health Perception and Quality of life (general mental health) was measured using The MOS-SF-36 with the general perceptions of health status subscale used to measure general health perceptions (5 items), changes in general health perception (1-item), and general mental health (5-items), on a 5-point Likert scale (total range of 11-55), with higher scores indicating positive perceptions of general health and general mental health. | Baseline and within 1 week post-intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |